Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities

Journal of Medical Economics

Volumn 16, Issue 8, 2013, Pages 1051-1060

  Coffin, Phillip O ^a   Sullivan, Sean D ^b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost effectiveness; Heroin; Naloxone; Overdose; Russian Federation

Indexed keywords

NALOXONE;

ADULT; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRIMINAL JUSTICE; DRUG COST; DRUG INTOXICATION; FEMALE; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; TUBERCULOSIS;

ADOLESCENT; ADULT; AGE FACTORS; COST-BENEFIT ANALYSIS; DRUG OVERDOSE; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NALOXONE; NARCOTIC ANTAGONISTS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; RUSSIA; TIME FACTORS; URBAN POPULATION; YOUNG ADULT;

EID: 84880519753     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.811080     Document Type: Article

References (82)

1. Sporer KA. Acute heroin overdose. Ann Intern Med 1999;130:584-90
2. Coffin PO. Overdose: a major cause of preventable death in central and Eastern Europe in Central Asia: recommendations and overview of the situation in Latvia, Kyrgyzstan, Romania, Russia and Tajikistan. Vilnius, Lithuania: Eurasian Harm Reduction Network, 2008
3. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001;285:45
4. Rhodes T, Sarang A. Drug treatment and the conditionality of HIV treatment access: a qualitative study in a Russian city. Addiction 2012;107:1827-36
5. Marshall BD, Milloy MJ, Wood E, et al. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011;377:1429-37
6. Coffin PO, Sherman S, Curtis M. Underestimated and overlooked: a global review of drug overdose and overdose prevention. London, England: International Harm Reduction Association, 2010
7. Strang J, Kelleher M, Best D, et al. Emergency naloxone for heroin overdose. BMJ 2006;333:614-5.
8. Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med 2007;49:172-7
9. Gonzva J, Prunet B, Deniel C, et al. Early antidote use associated with noninvasive ventilation in prehospital treatment of methadone intoxication. Am J Emerg Med 2013;31:448 e5-6.
10. Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008;103:979-89
11. Doe-Simkins M, Walley AY, Epstein A, et al. Saved by the nose: bystanderadministered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009;99:788-91
12. Piper TM, Stancliff S, Rudenstine S, et al. Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse 2008;43: 858-70
13. Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010;87:931-41
14. Sherman SG, Gann DS, Scott G, et al. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct J 2008;5:2-6
15. Maxwell S, Bigg D, Stanczykiewicz K, et al. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis 2006;25:89-96
16. Paone D, Heller D, Olson C, et al. Illicit drug use in New York City. NYC Vital Signs New York, NY: Department of Mental Health and Hygeine, 2010. p 1-4
17. Coffin PO, Tracy M, Bucciarelli A, et al. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med 2007;14:616-23
18. Stout NK, Knudsen AB, Kong CY, et al. Calibration methods used in cancer simulation models and suggested reporting guidelines. PharmacoEconomics 2009;27:533-45
19. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013;158:1-9
20. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
21. Huo D, Bailey SL, Ouellet LJ. Cessation of injection drug use and change in injection frequency: the Chicago Needle Exchange Evaluation Study. Addiction 2006;101:1606-13
22. Bruneau J, Brogly SB, Tyndall MW, et al. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction 2004; 99:727-37
23. Sergeev B, Karpets A, Sarang A, et al. Prevalence and circumstances of opiate overdose among injection drug users in the Russian Federation. J Urban Health 2003;80:212-9
24. Grau LE, Green TC, Torban M, et al. Psychosocial and contextual correlates of opioid overdose risk among drug users in St. Petersburg, Russia. Harm Reduct J 2009;6:17-28
25. Green TC, Grau LE, Blinnikova KN, et al. Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. Int J Drug Policy 2009;20:270-6
26. Kwon JA, Iversen J, Maher L, et al. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr 2009;51:462-9
27. Ochoa KC, Davidson PJ, Evans JL, et al. Heroin overdose among young injection drug users in San Francisco. Drug Alcohol Depend 2005;80:297-302
28. Jenkins LM, Banta-Green CJ, Maynard C, et al. Risk factors for nonfatal overdose at Seattle-area syringe exchanges. J Urban Health 2011;88:118-28
29. Galea S, Coffin PO. Drug overdose: new insights, innovative surveillance, and promising interventions. J Urban Health 2003;80:186-8
30. Zador D, Sunjic S, Darke S. Heroin-related deaths in New South Wales, 1992: toxicological findings and circumstances. Med J Aust 1996;164:204-7
31. Wu LT, Woody GE, Yang C, et al. Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Subst Abuse Rehabil 2011;2011:77-88
32. Open Health Institute. Harm reduction programs in the civilian and prison sectors of the Russian Federation: assessment of best practices. Moscow: World Bank, 2006
33. Musatov VA. Abstinence from drugs vs reducing harm. Sixth School for Journalists Writing on Health Issues. Pushkino School for Journalism: Pushkino, Russia, 2006
34. Cohen J. No opiate substitutes for the masses of IDUs. Science 2010;329:165-7
35. Hser YI. Drug use careers: recovery and mortality. In Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Substance use by older adults: estimates of future impact on the treatment system. OAS Analytic Series #A-21, DHHS Publication No. (SMA) 03-3763. Rockville, MD: SAMHSA 2002
36. Evans JL, Hahn JA, Lum PJ, et al. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug Alcohol Depend 2009;101:152-7
37. Pollini RA, McCall L, Mehta SH, et al. Non-fatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend 2006;83: 104-10
38. Darke S, Williamson A, Ross J, et al. Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study. J Urban Health 2007;84:283-91
39. Abdala N, Grund JP, Tolstov Y, et al. Can home-made injectable opiates contribute to the HIV epidemic among injection drug users in the countries of the former Soviet Union?. Addiction 2006;101:731-7
40. Darke S, Mills KL, Ross J, et al. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol Depend 2011;115:190-5
41. Stoove MA, Dietze PM, Jolley D. Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev 2009;28:347-52
42. Milloy MJ, Kerr T, Mathias R, et al. Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am J Drug Alcohol Abuse 2008;34:499-509
43. Gossop M, Griffiths P, Powis B, et al. Frequency of non-fatal heroin overdose: survey of heroin users recruited in non-clinical settings. BMJ 1996;313:402
44. Davidson PJ, McLean RL, Kral AH, et al. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health 2003;80:261-7345.
45. Coffin PO. Overdose and femoral injection among Seattle-area injection drug users. In: National Institute on Drug Abuse, ed. Epidemiologic trends in drug abuse. Proceedings of the Community Epidemiology Work Group. Rockville, MD, June 2011
46. Coffin PO, Galea S, Ahern J, et al. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction 2003;98:739-47
47. Avksentieva MV, Antonova NV, Arutyunov GP, et al. Procedure for clinical and economic evaluation of drug lists that are submitted for reimbursement coverage from public health care budget. Russia: Research center for clinical and economic evaluation and pharmacoeconomics of the Russian State Medical University; 2010
48. Tsarev SA. Annual Report: preventing opiate overdose among injecting drug users in Chapayevsk. Chapayevsk, Russian Federation: Open Society Institute, 2010
49. Gorbunova Y. Summary of naloxone distribution activities. Naberezhnye: Tamur Islamov Charitable Fund, 2010
50. Tufts G. Return of the ambulance. Moscow, Russia: Rossijskaya Gazeta, 2011
51. Russian Federation Ministry of Health and Social Development. Health/Medical Insurance; Information Letter on the formation and economic justification of territorial programs providing government guarantees for free healthcare for Russian citizens in 2011. Moscow, Russia: Russian Federation Ministry of Health and Social Development; 2012
52. Winter Y, Epifanova-Bertschi N, Sankowski R, et al. Health-related quality of life and its determinants in the urban Russian population with major depressive disorder: a cross-sectional study. Int J Psychiatry Med 2012;43:35-49
53. Nosyk B, Sun H, Guh DP, et al. The quality of eight health status measures were compared for chronic opioid dependence. J Clin Epidemiol 2010;63: 1132-44
54. Pyne JM, Tripathi S, French M, et al. Longitudinal association of preferenceweighted health-related quality of life measures and substance use disorder outcomes. Addiction 2011;106:507-15
55. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of costeffectiveness acceptability curves. Health Econ 2001;10:779-87
56. Tamatsukuri S, Suzuki T, Kasai K, et al. [A novel RNA capture method for the extraction of HCV-RNA]. Kansenshogaku Zasshi 1996;70:479-84
57. United States Agency for International Development. Russia: HIV/AIDS Health Profile. Moscow, Russia: USAID/Russia; 2010. p 4
58. Joint United Nations Programme on HIV/AIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS, 2010
59. Williams-Sherlock M. Universal access to HIV prevention, treatment, care, and support: 2011 Progress Report, Europe and Central Asia. Geneva: Joint United Nations Programme on HIV/AIDS, 2012
60. Krupitsky EM, Zvartau EE, Lioznov DA, et al. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia. Eur Addict Res 2006;12:12-19
61. World Health Organization. Global Tuberculosis Control: Russian Federation Country Profile. Geneva: World Health Organization, 2011
62. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006;101: 1499-508
63. Galea S, Worthington N, Piper TM, et al. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav 2006;31:907-12
64. Coffin PO, Coffin LM, Fitzpatrick T, et al. Drug overdose, lay naloxone, and HIV risk behaviors among persons who inject drugs. XIX International AIDS Conference. Washington, DC, 2012. Abstract#MOPE218
65. McAuley A, Best D, Taylor A, et al. From evidence to policy: The Scottish national naloxone programme. Drugs Educ Prev Policy 2012;19:309-19
66. Wall M, Schmidt E, Sarang A, et al. Sex, drugs and economic behaviour in Russia: a study of socio-economic characteristics of high risk populations. Int J Drug Policy 2011;22:133-9
67. Mackesy-Amiti ME, Ouellet LJ, Golub ET, et al. Predictors and correlates of reduced frequency or cessation of injection drug use during a randomized HIV prevention intervention trial. Addiction 2011;106:601-8
68. The future of harm reduction programmes in Russia. Lancet 2009;374:1213
69. Wagner KD, Valente TW, Casanova M, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy 2010;21:186-93
70. Davidson PJ, Ochoa KC, Hahn JA, et al. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. Addiction 2002;97: 1511-6
71. Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction 1996;91:405-11
72. Bohnert AS, Tracy M, Galea S. Characteristics of drug users who witness many overdoses: implications for overdose prevention. Drug Alcohol Depend 2012;120:168-73
73. Wampler DA, Molina DK, McManus J, et al. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care 2011;15:320-4
74. Strang J, Manning V, Mayet S, et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction 2008;103:1648-57
75. Tobin KE, Sherman SG, Beilenson P, et al. Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy 2009;20:131-6
76. Teesson M, Mills K, Ross J, et al. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2008;103:80-8
77. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000;90:1100-11
78. Vanagas G, Padaiga Z, Bagdonas E. Cost-utility analysis of methadone maintenance treatment in Lithuania. Medicina (Kaunas) 2010;46:286-92
79. Koshkina EA. Mortality associated with drug use. Use of Epidemiologic Methods for Drug User Mortality Research. Petrozavodsk, Russia: United Nations Office on Drugs and Crime, 2008
80. Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 1995;40:139-50
81. Hser YI, Hoffman V, Grella CE, et al. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001;58:503-8.
82. Vlahov D, Wang C, Ompad D, et al. Mortality risk among recent-onset injection drug users in five U.S. cities. Subst Use Misuse 2008;43:413-28